Medtronic's Hugo Robotic Surgery System Gains FDA Approval, Enters U.S. Market

Will the Urology Market Change?

Recently, Medtronic announced that itsHugo™ Robot-Assisted Urological Surgery System ReceivesFDAApproved for Marketing。

ThroughFDAApproval,Hugo RASThe system can be used for minimally invasive urological surgeries, including prostatectomy, nephrectomy, and cystectomy., these surgeries are performed approximately23Ten Thousand Cases。

Expand UROProof of Clinical Study for Experimental Device ExemptionHugo RASThe system meets the primary safety and effectiveness endpoints for urological surgeries, with results consistent with published literature.

Future，Medtronic Plans toHugo RASThe system's application in the United States is expanding to more surgical specialties and is expected to be used in general and gynecological surgeries after the initial urology examination.。

Vice President and General Manager of Medtronic Surgical RoboticsRajit KamalIndicates:"It's an incredibly exciting day for U.S. healthcare.FDACorrectHugo RAS"The system's approval means that hospitals now have more options to expand their robotic programs and increase patient access."

ForHugoThe revenue growth that will be generated has also made Medtronic more confident.

Previously,Chairman and Chief Executive Officer of MedtronicGeoff MarthaIndicates,"Driven by several enterprise growth drivers, we will achieve greater revenue growth in the second half of this year and beyond, including targetingAfibThePFAFranchise, HypertensionSymplicity™ Program,Hugo™ Robotic-Assisted Surgical SystemAndAltaviva™ Treats acute urinary incontinence."

According to the latest financial reports of the company,2025Q2MedtronicRevenue89.61Billion USD, reported growth6.6%`, Organic Growth`5.5%。

Surgical Robots Enter the Harvest Period of Dividends

Giants Face Off in Epic Showdown

United StatesYesThe world's largest surgical robot market. According to Frost & SullivanData，2020U.S. Surgical Robotics Market Size in [Year]46Billion US dollars,OccupyGlobal Market55.1%。

2000Year,Da Vinci Surgical RobotObtainFDAApproved, achieving legendary growth over the years and firmly holding the top position in surgical robotics.。

2025YearQ3Intuitive SurgicalIncome25.1Billion US dollars,Year-on-yearGrowth23%，Mainly due to the increased configuration of the da Vinci surgical system and its da Vinci andIonThe number of surgeries performed using endoluminal systems has increased (with a rise in the volume of da Vinci surgeries).19%，IonIncrease in Surgical Volume52%）。

MedtronicHugoSurgical RobotIn2019Years advanced, followed by in2021Year TakeCECertification, entering the European market. As of now，Hugo RASThe system has been implemented across five continents.30Used in tens of thousands of urological, gynecological, and general surgical procedures across multiple countries.

Nowadays, MedtronicHugoEntering the U.S. market, it will engage in a head-to-head competition with da Vinci, bringing changes to the long-standing market dominance held by da Vinci.

In addition,Johnson & JohnsonSoft Tissue RoboticsOTTAVA™Is also being continuously advanced.This Year4Month,Johnson & Johnson Announces Its Soft Tissue Surgical RobotOTTAVACompletion of First Patient Clinical Enrollment, this surgical robot last yearObtainFDAApproval for ImplementationIDEResearch。

Cavity mirror surgical robots are the earliest type of surgical robots to mature and also represent the largest细分 market within the surgical robot sector. In this field, Chinese enterprises have achieved some breakthroughs.

2021Since the year, WEGO, MicroPort Robot, Sizhe Rui,Refine Medical, including Shurui and a number of other surgical robot companies' products, have been approved for marketing in China.This year, the minimally invasive single-port surgical robot andRuilong Surgical、Agile Medical、Only PrecisionSurgical Robots Under Medical Company Get Approved One After Another。

The scale of China's surgical robot market is currentlyFar LowerInThe United States, but with the greatest growth potential。According to Frost & SullivanData，2020Scale of China's Endoscopic Surgical Robot Market in [Year]318.4Million Dollars, it is estimated that2026YearWillAchieve2315.3Million Dollars, duringCompound Annual Growth Rate39.2%。

The capital market has responded enthusiastically to the newly approved surgical robots produced in China.

9Month,Ruilong Surgical Announces Completion of Series A Financing Led by Johnson & Johnson InnovationDRound of financing, Lilly Asia Ventures (LAV), Yingtai Capital,Granite AsiaFollow-on investment, total financing amount reached6700Million USD.This isFollowing2025Completed at the beginning of the year byGranite AsiaLeading InvestmentCAfter the round of financingThe company'sAnother round of large-scale financing,Two transactionsTotal financing exceeds1Billion US dollars。

Johnson & Johnson Medical TechnologiesAlso withRuilong Surgical SignCompletedStrategic Cooperation Agreement: The two parties will combine the modular advantages of Ruilong Surgical's endoscopic surgical robot system with Johnson & Johnson's leading technology in the field of minimally invasive surgery.Launch Cooperation。

Agile MedicalHas also received capital favor.10Month, the companyAnnouncementCompleted several hundred million RMBBRound of Financing，Led by Mingxi Capital,Yuanhe Holdings, Licheng Investment, Nantong Investment Management followed up on the investment, and received support from the existing shareholder Qianji Capital,Yuanhe OriginContinuous additional investment。

The Multi-Power Competition in the Surgical Robot Market Has Officially Begun.

END